FDA New Drug Application for TLX591-CDx Proceeds to Review
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- TGA Priority Review Granted for Prostate Cancer Imaging
- ProstACT Phase III Study Clinical Development Update
- Telix and DuChemBio - South Korea Partnership
- Briefing for Investor call - TheraPharm GmbH Acquisition
- Acquisition of TheraPharm GmbH - Investor Call
Later from Telix Pharmaceuticals
- Telix Completes Acquisition of TheraPharm GmbH
- IP Agreement with U Southampton for access to TRALA data
- New Drug Submission filed with Health Canada for TLX591-CDx
- Appendix 4C and Activities Report for December 2020 Quarter
- Czech Republic Grants National Authorisation for TLX591 Kit
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals